Antimalarial drugs inhibit human 5-HT 3 and GABA A but not GABA C receptors

British Journal of Pharmacology

Volumn 153, Issue 8, 2008, Pages 1686-1696

  Thompson, A J ^a   Lummis, S C R ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Antagonist; Binding site; Chloroquine; Cys loop; GABA; Ligand docking; Malaria; Mefloquine; Quinine; Serotonin receptor

Indexed keywords

4 AMINOBUTYRIC ACID A ALPHA1 BETA2 GAMMA2 RECEPTOR; 4 AMINOBUTYRIC ACID A ALPHA1 BETA2 RECEPTOR; 4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID C RHO1 RECEPTOR; CHLOROQUINE; MEFLOQUINE; QUININE; SEROTONIN 3 RECEPTOR; SEROTONIN 3A RECEPTOR; SEROTONIN 3AB RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BLOOD; DRUG INHIBITION; DRUG POTENCY; ELECTROPHYSIOLOGY; FEMALE; IC 50; MALARIA; NONHUMAN; NUCLEOTIDE SEQUENCE; OOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; XENOPUS;

ANIMALS; ANTIMALARIALS; BINDING, COMPETITIVE; CELLS, CULTURED; CHLOROQUINE; ELECTROPHYSIOLOGY; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; MEFLOQUINE; OOCYTES; QUININE; RECEPTORS, GABA; RECEPTORS, GABA-A; RECEPTORS, SEROTONIN, 5-HT3; XENOPUS LAEVIS;

EID: 42149155410     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/bjp.2008.34     Document Type: Article

References (49)

1. Adelusi SA, Salako LA (1982). Tissue and blood concentrations of chloroquine following chronic administration in the rat. J Pharmacol 34: 733-735.
2. A receptor structure-function studies: a reexamination in light of new acetylcholine receptor structures. Int Rev Neurobiol 62: 1-43.
3. Ballestero JA, Plazas PV, Kracun S, Gomez-Casati ME, Taranda J, Rothlin CV et al. (2005). Effects of quinine, quinidine, and chloroquine on a9a10 nicotinic cholinergic receptors. Mol Pharmacol 68: 822-829.
4. 3 receptors by propofol: equilibrium and kinetic measurements. Neuropharmacology 39: 1064-1074.
5. 3 receptors in outside-out patches of N1E-115 neuroblastoma cells: basic properties and effects of pentobarbital. Neuropharmacology 36: 655-664.
6. Barnard EA, Skolnick P, Olsen RW, Mohler H, Sieghart W, Biggio G et al. (1998). International Union of Pharmacology. XV. Subtypes of gamma-aminobutyric acid A receptors: classification on the basis of subunit structure and receptor function. Pharmacol Rev 50: 291-313.
7. Baudry S, Pham YT, Baune B, Vidrequin S, Crevoisier C, Gimenez F et al. (1997). Stereoselective passage of mefloquine through the blood-brain barrier in the rat. J Pharm Pharmacol 49: 1086-1090.
8. 3A) and nicotinic acetylcholine receptors: the anomalous binding properties of nicotine. Biochemistry 41: 10262-10269.
9. A receptor: evidence for a beta-strand. J Neurosci 19: 4847-4854.
10. Bountra C, Gale JD, Gardner CJ, Jordan CC, Kilpatrick GJ, Twissell DJ et al. (1996). Towards understanding the aetiology and pathophysiology of the emetic reflex: novel approaches to antiemetic drugs. Oncology 53: 102-109.
11. Bray PG, Martin RE, Tilley L, Ward SA, Kirk K, Fidock DA (2005). Defining the role of PfCRT in Plasmodium falciparum chloroquine resistance. Mol Microbiol 56: 323-333.
12. Brejc K, van Dijk WJ, Klaassen RV, Schuurmans M, van Der Oost J, Smit AB et al. (2001). Crystal structure of an ACh-binding protein reveals the ligand-binding domain of nicotinic receptors. Nature 411: 269-276.
13. Cutting GR, Lu L, O'Hara BF, Kasch LM, Montrose-Rafizadeh C, Donovan DM et al. (1991). Cloning of the gamma-aminobutyric acid (GABA) rho 1 cDNA: a GABA receptor subunit highly expressed in the retina. Proc Natl Acad Sci USA 88: 2673-2677.
14. 3B subunit is a major determinant of serotonin-receptor function. Nature 397: 359-363.
15. Dellisanti CD, Yao Y, Stroud JC, Wang ZZ, Chen L (2007). Crystal structure of the extracellular domain of nAChR alpha1 bound to alpha-bungarotoxin at 1.94Å resolution. Nat Neurosci 10: 953-962.
16. Dow GS, Hudson TH, Vahey M, Koenig ML (2003). The acute neurotoxicity of mefloquine may be mediated through a disruption of calcium homeostasis and ER function in vitro. Malar J 2: 14.
17. 3B receptor subunit. J Biol Chem 274: 30799-30810.
18. Dzierszinski F, Coppin A, Mortuaire M, Dewailly E, Slomianny C, Ameisen JC et al. (2002). Ligands of the peripheral benzodiazepine receptor are potent inhibitors of Plasmodium falciparum and Toxoplasma gondii in vitro. Antimicrob Agents Chemother 46: 3197-3207.
19. C receptor rho subunits are heterogeneously expressed in the human CNS and form homoand heterooligomers with distinct physical properties. Eur J Neurosci 11: 41-50.
20. 3 receptor network after 20 years of research - evolving concepts in management of pain and inflammation. Eur J Pharmacol 560: 1-8.
21. 3A receptors in cells of the immune system. Scand J Rheumatol Suppl 119: 9-11.
22. Goldin LR (1992). Maintenance of Xenopus laevis and oocyte injection. In: Bernardo R, Iverson LE (eds). Methods in Enzymology vol. 207 Academic Press: New York, pp 267-279.
23. A receptor ligand-binding pocket. J Biol Chem 281: 24455-24461.
24. Leff P, Dougall IG (1993). Further concerns over Cheng-Prusoff analysis. Trends Pharmacol Sci 14: 110-112.
25. + channel determined by construction of multimeric cDNAs. Neuron 9: 861-871.
26. Liu L, Katz Y, Weizman R, Rosenberg B, Pasternak GW, Gavish M (1991). Interactions of chloroquine with benzodiazepine, gamma-aminobutyric acid and opiate receptors. Biochem Pharmacol 41: 1534-1536.
27. Lobel HO, Miani M, Eng T, Bernard KW, Hightower AW, Campbell CC (1993). Long-term malaria prophylaxis with weekly mefloquine. Lancet 341: 848-851.
28. C receptor. Chem Biol 12: 993-997.
29. Luzzi GA, Peto TE (1993). Adverse effects of antimalarials. An update. Drug Saf 8: 295-311.
30. Lynch L, Simpson KH (2001). Antiemetic drugs. The Royal College of Anaesthetists, bulletin 9 (September).
31. 3 receptor: heterogeneity in distribution and function among species. Mol Pharmacol 48: 407-416.
32. 3 serotonin receptor-like genes HTR3C, HTR3D and HTR3E. Gene 310: 101-111.
33. Niesler B, Walstab J, Combrink S, Moeller D, Kapeller J, Rietdorf J et al. (2007). Characterization of the novel human serotonin receptor subunits 5-HT3C, 5- HT3D and 5-HT3E. Mol Pharmacol 72: 8-17.
34. Olsen L, Pettersson I, Hemmingsen L, Adolph HW, Jorgensen FS (2004). Docking and scoring of metallo-beta-lactamases inhibitors. J Comput Aided Mol Des 18: 287-302.
35. Piper SN, Rohm KD, Papsdorf M, Maleck WH, Mattinger P, Boldt J (2002). Dolasetron reduces pain on injection of propofol. Anasthesiol Intensivmed Notfallmed Schmerzther 37: 528-531.
36. Ramharter M, Wernsdorfer WH, Kremsner PG (2004). In vitro activity of quinolines against Plasmodium falciparum in Gabon. Acta Trop 90: 55-60.
37. Rothlin CV, Lioudyno MI, Silbering AF, Plaza PV, Casati ME, Katz E et al. (2003). Direct interaction of serotonin type 3 receptor ligands with recombinant and native a9a10-containing nicotinic cholinergic receptors. Mol Pharmacol 63: 1067-1074.
38. Rothlin CV, Katz E, Verbitsky M, Elgoyhen AB (1999). The α9 nicotinic acetylcholine receptor shares pharmacological properties with type A gamma-aminobutyric acid, glycine, and type 3 serotonin receptors. Mol Pharmacol 55: 248-254.
39. Sali A, Blundell TL (1993). Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 234: 779-815.
40. Shi J, Blundell TL, Mizuguchi K (2001). FUGUE: sequence-structure homology recognition using environment-specific substitution tables and structure-dependent gap penalties. J Mol Biol 310: 243-257.
41. Sieb JP, Milone M, Engel AG (1996). Effects of the quinoline derivatives quinine, quinidine, and chloroquine on neuromuscular transmission. Brain Res 712: 179-189.
42. Taylor WR, White NJ (2004). Antimalarial drug toxicity: a review. Drug Saf 27: 25-61.
43. 3 receptors. Curr Pharm Des 12: 3615-3630.
44. 3 receptor as a therapeutic target. Expert Opin Ther Targets 11: 527-540.
45. 3 receptors. Br J Pharmacol 151: 666-667.
46. 3 receptor binding site using modeling and radioligand binding. J Biol Chem 280: 20476-20482.
47. Tzvetkov MV, Meineke C, Oetjen E, Hirsch-Ernst K, Brockmoller J (2007). Tissue-specific alternative promoters of the serotonin receptor gene HTR3B in human brain and intestine. Gene 386: 52-62.
48. Uhlemann A, Yuthavong Y, Fidock DA (2005). Mechanisms of antimalarial drug action and resistance. In: Sherman IW (ed). Molecular Approaches to Malaria. ASM Press: Washington, USA, pp 429-461.
49. Unwin N (2005). Refined structure of the nicotinic acetylcholine receptor at 4Å resolution. J Mol Biol 346: 967-989.